MediciNova Announces Phase 2 Clinical Trial Approval for IPF Therapy
Biopharmaceutical company MediciNova recently announced that MN-001 (tipelukast) has been approved for clinical trials by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe idiopathic pulmonary fibrosis (IPF). MN-001 is an orally-available small…